🎉 M&A multiples are live!
Check it out!

Passage Bio Valuation Multiples

Discover revenue and EBITDA valuation multiples for Passage Bio and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

Passage Bio Overview

About Passage Bio

Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative diseases.


Founded

2017

HQ

United States of America
Employees

60

Website

passagebio.com

Financials

LTM Revenue n/a

LTM EBITDA n/a

EV

-$27.5M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Passage Bio Financials

Passage Bio has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Passage Bio achieved revenue of n/a and an EBITDA of -$62.1M.

Passage Bio expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Passage Bio valuation multiples based on analyst estimates

Passage Bio P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a n/a XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$99.3M -$62.1M XXX XXX XXX
EBITDA Margin -Infinity% -Infinity% XXX XXX XXX
Net Profit -$136M -$102M XXX XXX XXX
Net Margin -Infinity% -Infinity% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Passage Bio Stock Performance

As of April 15, 2025, Passage Bio's stock price is $0.

Passage Bio has current market cap of $23.8M, and EV of -$27.5M.

See Passage Bio trading valuation data

Passage Bio Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
-$27.5M $23.8M XXX XXX XXX XXX $-0.96

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Passage Bio Valuation Multiples

As of April 15, 2025, Passage Bio has market cap of $23.8M and EV of -$27.5M.

Passage Bio's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Passage Bio's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Passage Bio and 10K+ public comps

Passage Bio Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV -$27.5M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA 0.4x XXX XXX XXX
P/E -0.4x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF 0.6x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Passage Bio Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Passage Bio Valuation Multiples

Passage Bio's NTM/LTM revenue growth is n/a

Passage Bio's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $1.1M for the same period.

Over next 12 months, Passage Bio's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Passage Bio's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Passage Bio and other 10K+ public comps

Passage Bio Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth -37% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $1.1M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Passage Bio Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Genomics & Personalized Medicine comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Passage Bio M&A and Investment Activity

Passage Bio acquired  XXX companies to date.

Last acquisition by Passage Bio was  XXXXXXXX, XXXXX XXXXX XXXXXX . Passage Bio acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Passage Bio

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Passage Bio

When was Passage Bio founded? Passage Bio was founded in 2017.
Where is Passage Bio headquartered? Passage Bio is headquartered in United States of America.
How many employees does Passage Bio have? As of today, Passage Bio has 60 employees.
Who is the CEO of Passage Bio? Passage Bio's CEO is Dr. William Chou, M.D..
Is Passage Bio publicy listed? Yes, Passage Bio is a public company listed on NAS.
What is the stock symbol of Passage Bio? Passage Bio trades under PASG ticker.
When did Passage Bio go public? Passage Bio went public in 2020.
Who are competitors of Passage Bio? Similar companies to Passage Bio include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Passage Bio? Passage Bio's current market cap is $23.8M
Is Passage Bio profitable? Yes, Passage Bio is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.